XML 53 R31.htm IDEA: XBRL DOCUMENT v3.10.0.1
SEGMENT INFORMATION (Tables)
9 Months Ended
Sep. 30, 2018
Segment Reporting [Abstract]  
Information About Reportable Segments and Reconciliation of Segment Net Sales to Consolidated Net Sales and Segment Pre-Tax Income to Consolidated Pre-Tax Income
The table below presents information about Edwards Lifesciences' reportable segments (in millions):
 
Three Months Ended   
September 30,
 
Nine Months Ended   
September 30,
 
2018
 
2017
 
2018
 
2017
Segment Net Sales
 

 
 

 
 

 
 

United States
$
518.5

 
$
470.4

 
$
1,510.2

 
$
1,413.9

Europe
191.6

 
167.8

 
608.1

 
614.3

Japan
95.4

 
84.0

 
288.4

 
257.1

Rest of World
96.8

 
87.1

 
290.2

 
261.4

Total segment net sales
$
902.3

 
$
809.3

 
$
2,696.9

 
$
2,546.7

Segment Operating Income
 

 
 

 
 

 
 

United States
$
353.0

 
$
303.2

 
$
1,010.5

 
$
921.4

Europe
90.9

 
75.3

 
295.6

 
306.9

Japan
55.0

 
46.4

 
171.8

 
145.2

Rest of World
28.3

 
24.7

 
89.6

 
77.4

Total segment operating income
$
527.2

 
$
449.6

 
$
1,567.5

 
$
1,450.9


The table below presents reconciliations of segment net sales to consolidated net sales and segment operating income to consolidated pre-tax income (in millions):
 
Three Months Ended   
September 30,
 
Nine Months Ended   
September 30,
 
2018
 
2017
 
2018
 
2017
Net Sales Reconciliation
 

 
 

 
 

 
 

Segment net sales
$
902.3

 
$
809.3

 
$
2,696.9

 
$
2,546.7

Foreign currency
4.3

 
12.2

 
48.2

 
0.1

Consolidated net sales
$
906.6

 
$
821.5

 
$
2,745.1

 
$
2,546.8

Pre-tax Income Reconciliation
 

 
 

 
 

 
 

Segment operating income
$
527.2

 
$
449.6

 
$
1,567.5

 
$
1,450.9

Unallocated amounts:
 

 
 

 
 

 
 

Corporate items
(274.6
)
 
(216.6
)
 
(800.3
)
 
(658.8
)
Special charges (Note 4)

 
(9.7
)
 

 
(9.7
)
Intellectual property litigation expenses
(7.9
)
 
(13.7
)
 
(19.1
)
 
(31.6
)
Foreign currency
4.2

 
4.4

 
5.4

 
2.5

Consolidated operating income
248.9

 
214.0

 
753.5

 
753.3

Non-operating (expense) income
(0.2
)
 
(2.2
)
 
9.7

 
(42.3
)
Consolidated pre-tax income
$
248.7

 
$
211.8

 
$
763.2

 
$
711.0

Enterprise-Wide Information
Enterprise-wide information is based on actual foreign exchange rates used in the Company's consolidated condensed financial statements.
 
Three Months Ended   
September 30,
 
Nine Months Ended   
September 30,
 
2018
 
2017
 
2018
 
2017
 
(in millions)
 
 
 
 
Net Sales by Geographic Area
 

 
 

 
 

 
 

United States
$
518.7

 
$
470.4

 
$
1,510.3

 
$
1,413.9

Europe
201.3

 
182.3

 
659.3

 
627.0

Japan
94.2

 
83.2

 
289.5

 
253.0

Rest of World
92.4

 
85.6

 
286.0

 
252.9

 
$
906.6

 
$
821.5

 
$
2,745.1

 
$
2,546.8

Net Sales by Major Product and Service Area
 

 
 

 
 

 
 

Transcatheter Heart Valve Therapy
$
557.8

 
$
481.2

 
$
1,694.3

 
$
1,507.9

Surgical Heart Valve Therapy
184.6

 
195.6

 
554.4

 
602.2

Critical Care
164.2

 
144.7

 
496.4

 
436.7

 
$
906.6

 
$
821.5

 
$
2,745.1

 
$
2,546.8


 
September 30, 2018
 
December 31, 2017
 
(in millions)
Long-lived Tangible Assets by Geographic Area
 

 
 

United States
$
617.6

 
$
608.7

Europe
33.2

 
28.4

Japan
6.9

 
7.6

Rest of World
198.9

 
139.7

 
$
856.6

 
$
784.4